Last viewed: INCY


Prices are updated after-hours



nasdaq:INCY Incyte Corporation

INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (1.9% 1m) (-23.6% 1y) (0.0% 2d) (-0.0% 3d) (-0.3% 7d) (-100.0% volume)
http://www.incyte.com
Sec Filling | Patents | 1456 employees

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Drugs
JAKAFI (ruxolitinib)
PEMAZYRE (pemigatinib)

add to today's watch list email alert is off






Press-releases


Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
Published: 2022-01-22 (Crawled : 00:20) - prnewswire.com
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology

tyvyt cel asco injection results
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: 2.8% H: 0.78% C: -0.92%

financial results report results
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Published: 2022-01-14 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $121.21 | twitter stocktwits trandingview |
Health Technology
| | O: -0.21% H: 0.98% C: 0.98%
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: 0.0%
ONCY | $1.97 | twitter stocktwits trandingview |
Health Technology
| | O: 0.65% H: 0.0% C: 0.0%
AZN | News | $60.17 | twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 0.0% C: 0.0%
PFE | $54.05 | twitter stocktwits trandingview |
Health Technology
| | O: -1.01% H: 0.0% C: 0.0%

treatment cancer breast cancer merge
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
Published: 2021-12-24 (Crawled : 11:00) - prnewswire.com
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology

tyvyt new drug application ces era drug cel lung cancer china therapy injection cancer
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology

tyvyt new drug application ces drug china
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology
| | O: 0.82% H: 0.92% C: 0.66%
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: 3.76% H: 3.79% C: 1.89%

phase 2 ces phase 2 results results
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 06:00) - prnewswire.com
LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 0.0% C: 0.0%
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: -2.44% H: 0.0% C: 0.0%

car-t era therapeutics presentation therapy iot
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 02:00) - prnewswire.com
LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 0.0% C: 0.0%
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: -2.44% H: 0.0% C: 0.0%

car-t era presentation therapy
Annual Changes to the Nasdaq-100 Index®
Published: 2021-12-11 (Crawled : 04:20) - globenewswire.com
FOX | $35.27 | twitter stocktwits trandingview |
Consumer Services

LCID | $38.72 | twitter stocktwits trandingview |

NDAQ | News | $179.97 | twitter stocktwits trandingview |
Finance

CDW | $188.98 | twitter stocktwits trandingview |
Technology Services

FTNT | $304.99 | twitter stocktwits trandingview |
Electronic Technology

CHKP | News | $124.66 | twitter stocktwits trandingview |
Technology Services

PANW | $519.67 | twitter stocktwits trandingview |
Electronic Technology

INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

DDOG | $130.01 | twitter stocktwits trandingview |
Technology Services

CERN | News | $91.49 | twitter stocktwits trandingview |
Technology Services

ZS | $250.67 | twitter stocktwits trandingview |
Technology Services

ABNB | $154.58 | twitter stocktwits trandingview |
Administrative and Support and ...

QQQ | $ | twitter stocktwits trandingview |
Miscellaneous

TCOM | $25.21 | twitter stocktwits trandingview |
Consumer Services

FOXA | $38.19 | twitter stocktwits trandingview |
Consumer Services

index
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
Published: 2021-12-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology
| | O: -0.84% H: 0.49% C: 0.36%
INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology
| | O: -1.43% H: 3.35% C: 2.19%

chinese era diabetes phase 1 results
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount
0001209191-21-049611 4 2021-08-04 Sell S 389 32040


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying